Article
Activation of the JAK/STAT Pathway Leads to BRAF Inhibitor Resistance in BRAFV600E Positive Thyroid Carcinoma.
Molecular cancer research : MCR - 1 May 2023
Limberg Jessica, Egan Caitlin E, Gray Katherine D, Singh Mandeep, Loewenstein Zachary, Yang Yanping, Riascos Maria Cristina, Al Asadi Hala, Safe Parima, El Eshaky Steve, Liang Heng, Ullmann Timothy M, Wang Weibin, Li Wei, Zhang Tuo, Xiang Jenny, Stefanova Dessislava, Jin Moonsoo M, Zarnegar Rasa, Fahey Thomas J, Min Irene M
Abstract excerpt
A subset of thyroid cancers, recurrent differentiated thyroid cancers and anaplastic thyroid cancer (ATC), are difficult to treat by thyroidectomy and systemic therapy. A common mutation in thyroid cancer, BRAFV600E, has targetable treatment options; however, the results have been disappointing in thyroid cancers compared with BRAFV600E melanoma, as thyroid cancers quickly become resistant to BRAFV600E inhibitor...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.